Schmid, Anke
Bucher, Felicitas
Liczenczias, Erika
Maslanka Figueroa, Sara
Müller, Bettina
Agostini, Hansjürgen http://orcid.org/0000-0002-0331-1109
Funding for this research was provided by:
Universitätsklinikum Freiburg
Article History
Received: 13 December 2021
Revised: 8 April 2022
Accepted: 15 April 2022
First Online: 13 May 2022
Declarations
:
: Ethics approval was obtained from Ethics committee of University of Freiburg/positive vote 03. March 2020. German clinical trials Register ID: DRKS00021031.
: Informed consent was obtained electronically from all participants completing the survey.
: Not applicable.
: Erika Liczenczias, Sara Maslanka Figueroa, and Bettina Müller are employees of Novartis Pharma GmbH. Hansjürgen Agostini received institutional funds from Novartis for scientific research. Felicitas Bucher received institutional funds from Roche for scientific research and from Bayer and Novartis for lectures. Anke Schmid declares not to have any conflicts of interest.